ClinicalTrials.gg
CompletedNCT06437171Updated Oct 28, 2026

FeNO as a Marker of Allergic Reactions to OFC and Response of OMA Treatment in Multiple FA

A Phase 4 interventional study of Omalizumab in Food Allergy, sponsored by AAADRS Clinical Research Center. Completed at 1 site in United States. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by AAADRS Clinical Research Center · Phase 4, Interventional, and Treatment

How we know · 3 judgments

Updated Oct 28, 2026Now CompletedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing omalizumab in Food Hypersensitivity — 4 open to participants now, 4 under way, none of them phase 3. Omalizumab · Food Hypersensitivity.

Enrollment
9th of 12
24 · median 34
Started
2024
with 1 other
Phase 4
5 of 12
2 open now
Registered
8th of 12
by date
Lead sponsor
1 of 12
AAADRS Clinical Research Center

Among the 12 studies testing omalizumab in Food Hypersensitivity, this one is the 9th largest by enrollment, is one of 2 that started in 2024, is one of 5 in phase 4, and was the 8th registered.

Food Hypersensitivity

378 studies on the registry are indexed under Food Hypersensitivity; 90 are open to participants now.

Browse Food Hypersensitivity studies →

Open to participants now

4 of the 12 studies testing omalizumab in Food Hypersensitivity are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About omalizumab

Omalizumab: first FDA approval 2003 (XOLAIR), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 53 Food Hypersensitivity studies recruiting now, 8 (15%) set no upper age limit and 41 (77%) stop at 75 or younger; 45 take children under 18; 17 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing omalizumab in Food Hypersensitivity, or all of them as a file.
02

Study summary

This is a Phase IV, open-label, single-center study to evaluate the change in FeNO as a marker of clinical response to OMA in participants with multiple FA.

Read the detailed description

This is a Phase IV, open-label, single-center study to evaluate the change in FeNO as a marker of clinical response to OMA in participants with multiple FA. Twenty (20) participants will be enrolled over a 9-month enrollment period from an allergy and asthma medical specialty clinic. Should the participant meet all eligibility criteria, then following the Screening Period, the participant will be dosed with OMA and asked to continue to follow their food avoidance regimen.

Participants will return to the clinic every two weeks for 16-weeks, and then every 2 or 4-weeks (depending on dosing) for the remaining 36-weeks, for a total of 52-weeks. Primary endpoint analyses will occur at Week 16 and Week 52.

Description of XOLAIR treatment schedule:

Omalizumab will be dosed according to the OUtMATCH Study dosing. Patients will be monitored for acute hypersensitivity reactions for at least 61 minutes after the end of the injection. Epinephrine and parenteral diphenhydramine must be readily available for immediate use if required to treat a hypersensitivity reaction; site personnel must be able to detect and treat such reactions. Patients with severe hypersensitivity reactions (e.g., stridor, angioedema, life-threatening change in vital signs) must be withdrawn from study treatment.

All adverse events of systemic hypersensitivity reactions or anaphylactoid or anaphylaxis reactions must be reported within 24 hours to the Sponsor.

03

Conditions studied

  • Food Allergy

Browse trials for

Keywords

  • Food Allergy
  • Multiple Food Allergies
  • Biomarker
04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must meet the following criteria for study entry:

    • Able and willing to provide written from patient and parent or guardian and to comply with the study protocol.
    • Age 6 years of age or older at Visit 1
    • Documented history of food allergy to one or more of the following foods based on SPT performed at baseline visit:

      • peanut
      • milk
      • egg
      • tree nuts (Walnut/Pecan, Cashew/Pistachio, Almond, Hazelnut, Brazil nut)

Exclusion criteria

Exclusion Criteria:

  • Patients who meet any of the following criteria will be excluded from study entry:

    • Diagnosis of asthma requiring maintenance medication, including inhaled , leukotriene modifiers, LABA/ICS, biologics medications (Intermittent asthma [Step 1] is allowed and defined according to the 2020 NAEPP guidelines (as 'asthma requiring only prn SABA use) and \< 80% of predicted normal.
    • Diagnosis of nasal polyps, cystic fibrosis or any respiratory condition that will skew normally occurring FeNO levels
    • FeNO (measured in ppb) is lower than a value expected for the age, height, and gender of the participant or inability to perform respiratory collection maneuver
    • Systemic steroids, leukotriene modifiers, or nasal steroids for any cause/diagnosis within 4 weeks of baseline
    • Biologic use, for any diagnosis, within five half-lives of Screening
    • Antibiotic use, systemic/oral/intramuscular, for any cause/diagnosis within 2 weeks of baseline
    • Active smoker, cigarette, cigar, vape, recreational, and/or prior 10 pack year history
    • Participant weight or IgE levels outside of the dosing table for OMA
    • Known history of anaphylaxis/ to OMA
    • Any medical condition that is serious or unstable that in the opinion of the PI could confound the study results and/or interfere with subject participation or adherence
    • Pregnant or breastfeeding, or intending to become pregnant during the study or within 60 days after the last dose of OMA
  • Women of must have a negative serum pregnancy test result during the screening period
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Other
    Open Label Injection of Omalizumab

    Omalizumab dose and frequency based on baseline patient weight and total IgE

    Biological: Omalizumab

Interventions

  • BiologicalOmalizumab

    Omalizumab dose and frequency based on baseline subject weight and total IgE

06

What researchers measure

Primary outcomes

  1. FeNO change from baseline to week 52

    biomarker

    Time frame: 1 year

Secondary outcomes

  1. Time to change from baseline FeNO during OFC

    biomarker

    Time frame: at baseline and at week 16

07

Study locations

1 site
  • AAADRS Clinical Research Center
    Coral Gables, Florida 33134, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jun 2024 to primary completion in Jul 2026, 25 months.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Jul 2026, on Oct 28, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2024
First posted
May 31, 2024
StartActual
Jun 3, 2024
Primary completionActual
Jul 20, 2026
CompletionActual
Jul 31, 2026was Dec 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 28, 2026
Study completion
Dec 2026→Jul 31, 2026 (actual)
Oct 28, 2026
Enrollment
20 (estimated)→24 (actual)
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Active, not recruiting→Completed
    Study completion Dec 2026→Jul 31, 2026 (now actual)
    Enrollment 20 (estimated)→24 (actual)
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06437171
Lead sponsor
AAADRS Clinical Research Center
Responsible party
Sponsor
First posted
May 31, 2024
Start date
Jun 3, 2024
Primary completion
Jul 20, 2026
Completion
Jul 31, 2026
Last update
Oct 28, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omalizumab

Start the discussion